NovoPen 6 / NovoPen Echo Plus
Novo Nordisk
What it is
Reusable connected pens for Novo Nordisk Penfill insulin cartridges. They store dose amount and timing for the last 800 dose events, including flow checks and transfer the log by NFC into compatible diabetes apps, where it can sit beside glucose data. They capture doses but do not calculate or recommend them.
Editorial review: .
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Dose guidance: A dose-memory tool, not a calculator: the pens do not recommend meal or correction doses or track active insulin themselves.[1]
- Important harms and treatment burden
- Read the safety discussion and original sources. A missing summary does not establish safety.
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Read the full discussion and original sources for follow-up duration and study limitations.
This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 88 × 18 + 12 × 20 + 48 × 15 + 75 × 12 + 72 × 15 + 58 × 10 + 50 × 10 = 5604; divide by total weight 100. Unrounded weighted result: 56.04.
Automatically stores units, date, and time for the last 800 dose events, including flow checks, rather than relying on a manual log.[1]
A dose-memory tool, not a calculator: the pens do not recommend meal or correction doses or track active insulin themselves.[1]
Compatible apps can display the injection history beside CGM or meter data, but glucose does not flow into the pen or drive advice.[1]
Echo Plus supports half-unit dosing while NovoPen 6 is the whole-unit model; the combined range covers both needs but the models are not interchangeable.[1]
Injection works like a conventional reusable pen and no continuous phone connection is needed, but transfer requires deliberately tapping the pen to an NFC device.[1]
Data can move to several major apps and clinical platforms, including Glooko and Dexcom Clarity, but the pen accepts only prescribed Novo Nordisk Penfill cartridges.[1]
Novo Nordisk has current Australian patient, use, and app-support pages for NovoPen 6. That evidence does not establish Echo Plus availability in Australia or live inventory at every pharmacy; neither model is US-approved, and app availability varies by country.[2]
These tools do not automate basal insulin. Scores reflect what the shipping product does for injection users: reliably capturing doses, turning glucose and insulin-on-board data into useful guidance, and reducing daily burden without hiding regional or insulin-cartridge lock-in.
The full picture
NovoPen 6 and NovoPen Echo Plus are conventional reusable insulin pens with one useful addition: an automatic memory. They store the units, date, and time of the last 800 dose events (including flow checks)—at least about three months—and transfer that history when the pen is tapped against an NFC-capable phone or reader.1
The receiving app can place injections beside blood-glucose or CGM data and share them with a clinic. Novo Nordisk lists integrations that include Glooko, FreeStyle LibreLink in supported markets, Dexcom/Glooko, Dexcom Clarity, and mySugr. That is data integration, not dose automation: neither pen calculates a bolus or tells the user how much insulin to take.1
Echo Plus is the half-unit model; NovoPen 6 uses whole-unit dosing. Both take Novo Nordisk insulin cartridges and are not approved in the United States. Availability and which receiving apps work are market-specific.1
There is bounded evidence for NovoPen 6 in Australia: Novo Nordisk Australia maintains a current patient page, local user guidance, and a connection page that lists FreeStyle LibreLink as compatible in Australia.2 Those pages do not establish Australian availability of NovoPen Echo Plus, and they do not prove that every pharmacy has NovoPen 6 stock.
Sources
- [1]NovoPen 6 and NovoPen Echo Plus product page · Manufacturer — Confirms automatic storage of the last 800 dose events (including flow checks), NFC transfer, app/data integrations, use with Novo Nordisk cartridges, and no US approval.
Novo Nordisk. NovoPen 6 and NovoPen Echo Plus.
- [2]NovoPen 6 — Australian patient and connection information · Manufacturer — Novo Nordisk Australia's current patient page documents NovoPen 6 and links to local use and connection guidance; the companion connection page lists FreeStyle LibreLink compatibility in Australia. This supports NovoPen 6 in Australia, not Echo Plus or universal pharmacy stock.
Novo Nordisk Australia. NovoPen 6 (current Australian patient, use and connection guidance; companion page lists FreeStyle LibreLink compatibility in Australia).